IDWeek 2012: Vaccines

A quadrivalent inactivated influenza vaccine has a similar safety and immunogenicity profile among children, adults, and seniors when compared with Fluzone, the currently licensed vaccine, according to the results of three clinical trials reported at IDWeek 2012.

Both formulations of a new adjuvant varicella-zoster virus vaccine were immunogenic and well tolerated when tested in adult autologous hematopoietic cell transplant recipients, according to a study presented during IDWeek 2012.

Two doses of the investigational hepatitis B vaccine, HEPLISAV, induced significantly earlier and higher rates of seroprotection than Engerix-B, according to study results at IDWeek 2012.

Patients who received an entirely acellular pertussis vaccine series had a “markedly increased risk of disease” compared with those receiving even 1 dose of whole-cell pertussis vaccine, investigators reported during IDWeek 2012.

PCV 13, a 13-valent pneumococcal conjugate vaccine, showed a favorable safety profile and immunogenicity when administered concomitantly with DTaP, a report at at IDWeek 2012 demonstrated.

Results from a Phase 2 study reported on at IDWeek 2012 showed that the 5555 formulation of tetravalent dengue vaccine elicits the highest serpositivity rates and balanced response against all four serotypes with a satisfactory safety profile.

At IDWeek 2012, study researchers presented data showing that MenACWY-CRM, a quadrivalent meningococcal conjugate vaccine, has been shown to be highly immunogenic and well tolerated across age groups.